武汉佰乐博生物技术有限公司

3

手机商铺

qrcode
商家活跃:
产品热度:
  • NaN
  • 0
  • 0
  • 2
  • 2

武汉佰乐博生物技术有限公司

入驻年限:3

  • 联系人:

    钱女士

  • 所在地区:

    湖北 武汉市 江夏区

  • 业务范围:

    试剂、抗体、细胞库 / 细胞培养、ELISA 试剂盒、耗材、原辅料包材

  • 经营模式:

    经销商

在线沟通
推荐产品

Anti-Human PSPN Polyclonal Antibody

品牌:AntibodySystem

¥1680

咨询

Anti-Human CREBL2 Polyclonal Antibody

品牌:AntibodySystem

¥1680

咨询

Anti-ADCY9 Polyclonal Antibody

品牌:AntibodySystem

¥1680

咨询

Anti-OGA Polyclonal Antibody

品牌:AntibodySystem

¥1680

咨询

Anti-Human GMDS Polyclonal Antibody

品牌:AntibodySystem

¥1680

咨询
查看全部产品

公司新闻/正文

Anti-CD19 (FMC63) CAR特异性抗体蛋白

177 人阅读发布时间:2025-03-05 17:28

Anti-CD19 (FMC63) CAR特异性抗体蛋白

一、中文名称:Anti-CD19 (FMC63)CD19抗体,CAR特异性抗体蛋白

 

二、产品描述

FMC63抗体是一种针对人CD19的鼠单克隆抗体。CD19是目前CAR-T细胞治疗领域中应用最广泛的靶点,大量研究表明,CD19是治疗B细胞急性淋巴细胞白血病(B-ALL)、慢性淋巴细胞白血病(CLL)和B细胞淋巴瘤等肿瘤有效且安全的靶点。而FMC63抗体的出现,使得CAR-T细胞治疗更加精准、安全。

 

三、相关产品

Anti-FMC63 scFv Monoclonal Antibody (SAA1996) (RAD10801)

Anti-Human CD19 scFv Antibody (FMC63) (RHD10803)

Anti-FMC63 scFv Monoclonal Antibody (SAA2162) (RAD10803)

Anti-Human CD19 Antibody (FMC63) (FHD10840)

 

四、产品详情

名称:Anti-FMC63 scFv Monoclonal Antibody (SAA1996) (RAD10801)

别名:FMC63B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, Anti-FMC63

货号:RAD10801

宿主:Rabbit

同种型:IgG

克隆类型:Monoclonal

靶标:Anti-human CD19 antibody clone FMC63, Idiotypic antibody

浓度:0.43 mg/ml

内毒素水平:Please contact with the lab for this information.

纯度:>95% as determined by SDS-PAGE.

纯化方式:Protein A/G purified from cell culture supernatant.

Accession号:P15391

克隆号:SAA1996

应用:ELISA

状态:Liquid

保存溶液:0.01M PBS, pH 7.4.

稳定性和存储:Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. (RAD10801)

 

五、参考文献:

Solving the mystery of the FMC63-CD19 affinity. PMID: 38155191

CD19 CAR antigen engagement mechanisms and affinity tuning. PMID: 36867678

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. PMID: 31959992

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line. PMID: 33271901

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. PMID: 33021872

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. PMID: 35981465

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. PMID: 31477906

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. PMID: 38066564

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. PMID: 32894185

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. PMID: 36453632

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy. PMID: 37297020

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. PMID: 36875091

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. PMID: 35222427

Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy. PMID: 33432627

Fully human CD19-specific chimeric antigen receptors for T-cell therapy. PMID: 28202953

Stealth transgenes enable CAR-T cells to evade host immune responses. PMID: 38724463

Preparation and characterization of a chimeric CD19 monoclonal antibody. PMID: 1725979

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. PMID: 33023981

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells. PMID: 38659938

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. PMID: 38475814

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. PMID: 18676854

CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. PMID: 38745250

Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. PMID: 9566763

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells. PMID: 37206593

Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. PMID: 35755944

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design. PMID: 31702909

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. PMID: 33632869

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. PMID: 35117999

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. PMID: 33843201

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. PMID: 35355931

 

详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司

 

武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂,旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。

试剂 | 耗材 | 定制 | 实验服务 | 供应链

免费热线:027-65279366 /18108604356

 

上一篇

肺癌及卵巢癌潜力靶点SLC34A2/NaPi2b

下一篇

流行性乙型脑炎病毒(Japanese Encephalitis Virus/JEV)相关重组蛋白和抗体

更多资讯

我的询价